DOCSLIB.ORG

CORTICOSTEROIDS—GLUCOCORTICOID EFFECTS (Veterinary—Systemic)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CORTICOSTEROIDS—GLUCOCORTICOID EFFECTS (Veterinary—Systemic) CORTICOSTEROIDS—GLUCOCORTICOID EFFECTS (Veterinary—Systemic) This monograph contains information on the following: cell type.{R-30} A variety of glucocorticoids have been developed in Dexamethasone; Flumethasone; Hydrocortisone; Isoflupredone; an effort to vary the intensity and duration of effects and to Methylprednisolone; Prednisolone; Prednisone; Triamcinolone. decrease mineralocorticoid effects. However, systemic administration of these drugs is not a specifically targeted therapy Some commonly used brand names are: and should be structured to minimize unwanted effects and to For veterinary-labeled products— maximize therapeutic benefits. Cortalone Predef 2X Guidelines for use of glucocorticoids provided by product labeling [Triamcinolone] [Isoflupredone] range from broad to specific, depending on the product. A label Depo-Medrol PrednisTab may only state that a product is for use when an anti-inflammatory [Methylprednisolone] [Prednisolone] drug or adrenal glucocorticoid is needed or, alternatively, the label Dexamethasone 2 Predsone-5 [Prednisone] may list relatively specific indications for use.{R-18; 23} Many [Dexamethasone] product labels state that treatment of conditions known to be Dexamethasone 5 Rafter Dex responsive to anti-inflammatory glucocorticoids is indicated but [Dexamethasone] [Dexamethasone] then also list specific disorders for which the medication is known Dexasone Solu-Delta-Cortef to be effective.{R-4; 8; 11; 12; 14; 16; 17; 20; 22} For clarity, specific [Dexamethasone] [Prednisolone] indications noted on product labeling are listed in this section as Dexium [Dexamethasone] TriAcet [Triamcinolone] Accepted labeled indications and those not specifically named in Dexium SP Triamtabs U.S. or Canadian labeling are marked with an ELUS or ELCAN [Dexamethasone] [Triamcinolone] designation, respectively. However, it should be noted that Dexone [Dexamethasone] Uni-Dex products that are labeled for use in the treatment of general [Dexamethasone] inflammation might also be considered efficacious in the Dextab [Dexamethasone] Unimed treatment of more specific indications, such as musculoskeletal [Methylprednisolone] inflammation, for which it may not be listed because that specific Flucort [Flumethasone] Uni-Pred 50 type of inflammation is not mentioned on product labeling. [Prednisolone] Medrol Vetacortyl Accepted [Methylprednisolone] [Methylprednisolone] Adrenocortical insufficiency, acute (treatment)—Glucocorticoids are Methysone 40 Vetalog [Triamcinolone] indicated in the treatment of acute adrenocortical insufficiency [Methylprednisolone] (Addison’s disease); however, the mineralocorticoid effect will vary from product to product. For that small percentage of dogs For human-labeled products— with only glucocorticoid deficiency, long-term replacement can A-methaPred Dexone [Dexamethasone] be performed without a need for mineralocorticoid; however, for [Methylprednisolone] the majority of dogs, mineralocorticoid replacement is necessary. Cortef [Hydrocortisone] Emo Cort Hydrocortisone, methylprednisolone, prednisolone, and [Hydrocortisone] prednisone{R-34; 145} produce minor mineralocorticoid effects in Decadron Hydrocortone addition to their glucocorticoid effects and may adequately [Dexamethasone] [Hydrocortisone] reverse electrolyte imbalances when administered in conjunction Dexasone Solu-Medrol with intravenous sodium chloride solution; however, [Dexamethasone] [Methylprednisolone] methylprednisolone, prednisolone, and prednisone are considered insufficient for long-term control of the potassium-retention or Note: For a listing of dosage forms and brand names by country sodium and chloride losing effects of most cases of primary availability, see the Dosage Forms section(s). adrenocortical insufficiency{R-8} and a mineralocorticoid-specific medication is generally indicated. Category: In acute adrenocortical insufficiency, a rapidly acting parenteral Abortifacient—Dexamethasone. corticosteroid with the most mineralocorticoid effect available Anti-inflammatory agent (steroidal)—Dexamethasone; should be administered in conjunction with vascular volume Flumethasone; Hydrocortisone; Isoflupredone; expansion using isotonic saline.{R-213} Relative mineralocorticoid Methylprednisolone; Prednisolone; Prednisone; effect from the most to the least potency is hydrocortisone > Triamcinolone. prednisolone/prednisone > methylprednisolone > Diagnostic aid (hyperadrenocorticism)—Dexamethasone. dexamethasone.{R-38; 188} Gluconeogenic agent—Dexamethasone; Flumethasone; Cats: ELCANMethylprednisolone tabletsEL, ELUS,CANhydrocortisone Isoflupredone; Prednisolone. tabletsEL, prednisolone sodium succinate injection, Immunosuppressant—Prednisolone; Prednisone. ELUS,CANprednisolone tabletsEL, and ELUS,CANprednisone tabletsEL Parturifacient—Dexamethasone; Flumethasone. are indicated in the treatment of acute adrenocortical insufficiency.{R-9; 14; 193} Indications Dogs: Prednisolone sodium succinate is indicated in the treatment Note: The text between ELUS and EL describes uses that are not included of acute adrenocortical insufficiency when a rapid effect is in U.S. product labeling. Text between ELCAN and EL describes uses necessary.{R-7; 9} ELCANMethylprednisolone tabletsEL, that are not included in Canadian product labeling. ELCANprednisolone tabletsEL, ELUS,CANhydrocortisone tabletsEL, ELUS,CAN EL The ELUS or ELCAN designation can signify a lack of product and prednisone tablets are also indicated in the {R-8; 14; 100; 193; availability in the country indicated. See the Dosage Forms treatment of acute adrenocortical insufficiency. 195} section of this monograph to confirm availability. Horses: Dexamethasone sodium phosphate is indicated for use in situations in which a rapid adrenocortical effect is needed;{R- General considerations 11} Glucocorticoids potentially affect every cell in the body and produce a however, it provides no significant mineralocorticoid ELUS,CAN EL wide spectrum of effects depending on tissue concentration and effect. Prednisolone and prednisone have been used in the treatment of adrenocortical insufficiency. © 2008 The United States Pharmacopeial Convention All rights reserved 1 Allergic disorders (treatment)—Many glucocorticoids are likely to be flumethasone injection, methylprednisolone acetate injectable effective in the treatment of allergic reactions; however, the suspension, ELCANmethylprednisolone tabletsEL, prednisolone formulation should be chosen carefully to provide the onset of sodium succinate, ELUS,CANprednisolone tabletsEL, action, duration of action, and side effect profile to fit the type of ELUSprednisone tabletsEL, ELCANtriamcinolone acetonide reaction being treated. For example, for anaphylactic reactions, injectable suspensionEL, and ELCANtriamcinolone tabletsEL are corticosteroids play a secondary role to epinephrine and fluid indicated in the treatment of acute and chronic dermatoses of therapy. If corticosteroids are employed in the treatment of varying etiologies and the associated inflammation, irritation, anaphylaxis, short-acting water soluble formulations are and pruritus.{R-4; 9; 12; 14-18; 20; 22; 28} ELCANMethylprednisolone recommended. tablets are labeled for the treatment of otitis externa.EL{R-14} US Cats: Dexamethasone injection, methylprednisolone acetate Dogs: Dexamethasone injection, EL dexamethasone tabletsEL, injectable suspension, ELCANmethylprednisolone tabletsEL, flumethasone injection, methylprednisolone acetate injectable CAN prednisolone sodium succinate, ELCANtriamcinolone acetonide suspension, EL methylprednisolone tabletsEL, US injectable suspensionEL, and ELCANtriamcinolone tabletsEL are EL prednisolone acetate injectable suspensionEL, prednisolone CAN US indicated in the treatment of allergic conditions.{R-7; 9; 14-16; 20; sodium succinate, EL prednisolone tabletsEL, EL prednisone CAN 22} ELUS,CAN EL ELUS EL EL EL Flumethasone, prednisolone , and prednisone tablets , triamcinolone acetonide injectable CAN should also be effective in the treatment of allergic suspensionEL, and EL triamcinolone tabletsEL are indicated in disorders.{R-100; 194} the treatment of acute and chronic dermatoses of varying Cattle: Isoflupredone acetate injectable suspension and etiologies and the associated inflammation, irritation, and {R-4; 8-10; 12; 14-18; 20; 22; 28} dexamethasone injection are indicated in the treatment of pruritus. Flumethasone injection, allergic conditions.{R-6; 23; 24} ELUS,CANAlthough they are not methylprednisolone acetate injectable suspension, CAN CAN labeled for use in cattle in the U.S., flumethasone, EL methylprednisolone tabletsEL, and EL prednisolone {R-8; 14-18} prednisolone, and prednisone should also be effective in the tabletsEL are labeled for the treatment of otitis externa. treatment of allergic disorders.EL Disk disease, intervertebral (treatment)—Dogs: Dexamethasone Dogs: Dexamethasone injection, flumethasone injection,{R-18} injection and flumethasone injection are indicated as supportive methylprednisolone acetate injectable suspension, therapy in the treatment of intervertebral disk disease (disk ELCANmethylprednisolone tabletsEL, prednisolone sodium syndrome).{R-4; 18} But it should be noted that high dosages of succinate, ELCANprednisolone tabletsEL, ELCANtriamcinolone dexamethasone carry a risk of severe adverse effects.{R-166} acetonide injectable suspensionEL, and ELCANtriamcinolone Therapy should be tailored to the type of disk dysfunction and tabletsEL are indicated in the treatment of allergic clinical signs.
Load more

Recommended publications
  • Zhejiang Xianju Pharmaceutical Co. Ltd
    No.1, Xianyao Road, Xianju, Zhejiang, China, 317300 Xianju Pharma Outline Outline I. Brief Introduction II. Quality Unit III. Production System IV. EHS System I. Brief Introduction Xianju Pharma Zhejiang Xianju Pharmaceutical Co., Ltd. A professional manufacturer of steroids and hormone products with largest scale and maximum varieties in China. A state-designated manufacturer of contraceptive drugs in China. Company Milestones Jan 1972 Foundation of company May 1997 Incorporated into Zhejiang Medicine Co., Ltd Oct. 1999 Listed in Shanghai Stock Market Jun. 2000 Reorganized into Xianju Pharmaceutical Co., Ltd Dec. 2001 Reformed to Zhejiang Xianju Pharmaceutical Co., Ltd Jan. 2010 listed in Shenzhen Stock Market Location of Xianju There are six airports around Shanghai Xianju, which makes us easily accessible for our partners. Headquarter Hangzhou Located in Xianju, Taizhou City Ningbo Yangfu Site (FPPs) Located in Yangfu, Xianju, Taizhou Yiwu City 6.8km from headquarter Duqiao Site (APIs) Located in LinHai, TaiZhou City, 82.9km from headquarter Taizhou Wenzhou Yangfu Site (APIs) Under construction, finish at 2017 Company Organization General Manager Vice G.M for Vice G.M Vice G.M for Vice G.M for Vice G.M for Quality Director Sales for Market Administration Finance Technology Finance Dept Finance Dept Application Tech Dept Endineering Construction Domestic DrugRegistrationDept. Research& Development Dept. Marketing Dept. Marketing Quality Control Quality Domestic Trading Dept International TradeDep Quality Assurance For FPP Quality Assurance For API Regulatory AffairsDept Human Resource Dept Information Technology Dept Dept Enterprise Management Dept Affairs Administrative Taizhou Xianju Quality System Quality Xianju Taizhou . t G.M. Assistant EHS Dept Production Management Dept G.M.
    [Show full text]
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Docetaxel with Prednisone Or Prednisolone for the Treatment of Prostate Cancer ISSN 1366-5278 Feedback Your Views About This Report
    Health Technology Assessment Health Technology Health Technology Assessment 2007; Vol. 11: No. 2 2007; 11: No. 2 Vol. Docetaxel with prednisone or prednisolone for the treatment of prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer Feedback The HTA Programme and the authors would like to know R Collins, E Fenwick, R Trowman, R Perard, your views about this report. The Correspondence Page on the HTA website G Norman, K Light, A Birtle, S Palmer (http://www.hta.ac.uk) is a convenient way to publish and R Riemsma your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website. We look forward to hearing from you. January 2007 The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, Health Technology Assessment University of Southampton, NHS R&D HTA Programme Southampton, SO16 7PX, UK. HTA Fax: +44 (0) 23 8059 5639 Email: [email protected] www.hta.ac.uk http://www.hta.ac.uk ISSN 1366-5278 HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.
    [Show full text]
  • 1 Progesterone: an Enigmatic Ligand for the Mineralocorticoid Receptor
    Progesterone: An Enigmatic Ligand for the Mineralocorticoid Receptor Michael E. Baker1 Yoshinao Katsu2 1Division of Nephrology-Hypertension Department of Medicine, 0735 University of California, San Diego 9500 Gilman Drive La Jolla, CA 92093-0735 2Graduate School of Life Science Hokkaido University Sapporo, Japan Correspondence to: M. E. Baker; E-mail: [email protected] Y. Katsu; E-mail: [email protected] Abstract. The progesterone receptor (PR) mediates progesterone regulation of female reproductive physiology, as well as gene transcription in non-reproductive tissues, such as brain, bone, lung and vasculature, in both women and men. An unusual property of progesterone is its high affinity for the mineralocorticoid receptor (MR), which regulates electrolyte transport in the kidney in humans and other terrestrial vertebrates. In humans, rats, alligators and frogs, progesterone antagonizes activation of the MR by aldosterone, the physiological mineralocorticoid in terrestrial vertebrates. In contrast, in elephant shark, ray-finned fishes and chickens, progesterone activates the MR. Interestingly, cartilaginous fishes and ray-finned fishes do not synthesize aldosterone, raising the question of which steroid(s) activate the MR in cartilaginous fishes and ray-finned fishes. The simpler synthesis of progesterone, compared to cortisol and other corticosteroids, makes progesterone a candidate physiological activator of the MR in elephant sharks and ray-finned fishes. Elephant shark and ray-finned fish MRs are expressed in diverse tissues, including heart, brain and lung, as well as, ovary and testis, two reproductive tissues that are targets for progesterone, which together suggests a multi-faceted physiological role for progesterone activation of the MR in elephant shark and ray-finned fish.
    [Show full text]
  • Glucocorticoid Receptor Blockade Normalizes Hippocampal Alterations and Cognitive Impairment in Streptozotocin- Induced Type 1 Diabetes Mice
    Neuropsychopharmacology (2009) 34, 747–758 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org Glucocorticoid Receptor Blockade Normalizes Hippocampal Alterations and Cognitive Impairment in Streptozotocin- Induced Type 1 Diabetes Mice ,1,2 1 1 2 2 Yanina Revsin* , Niels V Rekers , Mieke C Louwe , Flavia E Saravia , Alejandro F De Nicola , 1 1 E Ron de Kloet and Melly S Oitzl 1 Division of Medical Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University Medical Center, Leiden, The Netherlands; 2 Laboratory of Neuroendocrine Biochemistry, IBYME, Buenos Aires, Argentina Type 1 diabetes is a common metabolic disorder accompanied by an increased secretion of glucocorticoids and cognitive deficits. Chronic excess of glucocorticoids per se can evoke similar neuropathological signals linked to its major target in the brain, the hippocampus. This deleterious action exerted by excess adrenal stress hormone is mediated by glucocorticoid receptors (GRs). The aim of the present study was to assess whether excessive stimulation of GR is causal to compromised neuronal viability and cognitive performance associated with the hippocampal function of the diabetic mice. For this purpose, mice had type 1 diabetes induced by streptozotocin (STZ) administration (170 mg/kg, i.p.). After 11 days, these STZ-diabetic mice showed increased glucocorticoid secretion and hippocampal alterations characterized by: (1) increased glial fibrillary acidic protein-positive astrocytes as a marker reacting to neurodegeneration, (2) increased c-Jun expression marking neuronal activation, (3) reduced Ki-67 immunostaining indicating decreased cell proliferation. At the same time, mild cognitive deficits became obvious in the novel object-placement recognition task.
    [Show full text]
  • Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial Colin M
    Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial Colin M. Parker, MBChB, DCH, MRCPCH, FACEM,a,b Matthew N. Cooper, BCA, BSc, PhDc OBJECTIVES: The use of either prednisolone or low-dose dexamethasone in the treatment of abstract childhood croup lacks a rigorous evidence base despite widespread use. In this study, we compare dexamethasone at 0.6 mg/kg with both low-dose dexamethasone at 0.15 mg/kg and prednisolone at 1 mg/kg. METHODS: Prospective, double-blind, noninferiority randomized controlled trial based in 1 tertiary pediatric emergency department and 1 urban district emergency department in Perth, Western Australia. Inclusions were age .6 months, maximum weight 20 kg, contactable by telephone, and English-speaking caregivers. Exclusion criteria were known prednisolone or dexamethasone allergy, immunosuppressive disease or treatment, steroid therapy or enrollment in the study within the previous 14 days, and a high clinical suspicion of an alternative diagnosis. A total of 1252 participants were enrolled and randomly assigned to receive dexamethasone (0.6 mg/kg; n = 410), low-dose dexamethasone (0.15 mg/kg; n = 410), or prednisolone (1 mg/kg; n = 411). Primary outcome measures included Westley Croup Score 1-hour after treatment and unscheduled medical re-attendance during the 7 days after treatment. RESULTS: Mean Westley Croup Score at baseline was 1.4 for dexamethasone, 1.5 for low-dose dexamethasone, and 1.5 for prednisolone. Adjusted difference in scores at 1 hour, compared with dexamethasone, was 0.03 (95% confidence interval 20.09 to 0.15) for low-dose dexamethasone and 0.05 (95% confidence interval 20.07 to 0.17) for prednisolone.
    [Show full text]
  • Penetration of Synthetic Corticosteroids Into Human Aqueous Humour
    Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec­ trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu­ orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh­ used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under­ preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou­ available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography).
    [Show full text]
  • Mineralocorticoid Receptor Mutations
    234 1 M-C ZENNARO and MR mutations 234:1 T93–T106 Thematic Review F FERNANDES-ROSA 30 YEARS OF THE MINERALOCORTICOID RECEPTOR Mineralocorticoid receptor mutations Maria-Christina Zennaro1,2,3 and Fabio Fernandes-Rosa1,2,3 Correspondence 1INSERM, Paris Cardiovascular Research Center, Paris, France should be addressed 2Université Paris Descartes, Sorbonne Paris Cité, Paris, France to M-C Zennaro 3Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, Email Paris, France maria-christina.zennaro@ inserm.fr Abstract Aldosterone and the mineralocorticoid receptor (MR) are key elements for maintaining Key Words fluid and electrolyte homeostasis as well as regulation of blood pressure. Loss-of- f mineralocorticoid function mutations of the MR are responsible for renal pseudohypoaldosteronism type receptor 1 (PHA1), a rare disease of mineralocorticoid resistance presenting in the newborn with f pseudohypoaldosteronism type 1- PHA1 weight loss, failure to thrive, vomiting and dehydration, associated with hyperkalemia f aldosterone and metabolic acidosis, despite extremely elevated levels of plasma renin and f hormone receptors aldosterone. In contrast, a MR gain-of-function mutation has been associated with a f nuclear receptor familial form of inherited mineralocorticoid hypertension exacerbated by pregnancy. In Endocrinology addition to rare variants, frequent functional single nucleotide polymorphisms of the of MR are associated with salt sensitivity, blood pressure, stress response and depression in the general population. This review will summarize our knowledge on MR mutations in Journal PHA1, reporting our experience on the genetic diagnosis in a large number of patients performed in the last 10 years at a national reference center for the disease.
    [Show full text]
  • Patient Leaflet: Information for the User Methylprednisolone-Teva 40 Mg
    Patient leaflet: Information for the user Methylprednisolone-Teva 40 mg powder for solution for injection Methylprednisolone-Teva 125 mg powder for solution for injection Methylprednisolone-Teva 500 mg powder for solution for injection Methylprednisolone-Teva 1000 mg powder for solution for injection methylprednisolone Read all of this leaflet carefully before you are given this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, or pharmacist or nurse. • If you get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Methylprednisolone-Teva is and what it is used for 2. What you need to know before you are given Methylprednisolone-Teva 3. How to use Methylprednisolone-Teva 4. Possible side effects 5. How to store Methylprednisolone-Teva 6. Contents of the pack and other information 1. What Methylprednisolone-Teva is and what it is used for Methylprednisolone is the active substance of Methylprednisolone powder for solution for injection. Methylprednisolone-Teva contains Methylprednisolone Sodium Succinate. Methylprednisolone belongs to a group of medicines called corticosteroids (steroids). Corticosteroids are produced naturally in your body and are important for many body functions. Boosting your body with extra corticosteroid such as Methylprednisolone-Teva can help following surgery (e.g. organ transplants), flare-ups of the symptoms of multiple sclerosis or other stressful conditions. These include inflammatory or allergic conditions affecting the: brain caused by a tumour or meningitis bowel and gut e.g.
    [Show full text]
  • Efficiency of Different Methods of Estrus Synchronization Followed by Fixed Time Artificial Insemination in Persian Downy Does
    DOI: 10.21451/1984-3143-AR825 Anim. Reprod., v.14, n.2, p.413-417, Apr./Jun. 2017 Efficiency of different methods of estrus synchronization followed by fixed time artificial insemination in Persian downy does Majid Hashemi1, 2, 3, Mazaher Safdarian2 1Razi Vaccine and Serum Research Institute, Shiraz Branch, Agricultural Research, Education and Extension Organization (AREEO), Shiraz, Iran. 2Animal Science Research Department, Fars Agricultural and Natural Resource Research and Education Center, Agricultural Research, Education and Extension Organization (AREEO), Shiraz, Iran. Abstract estrus synchronization can play an important role for managing production system, allowing the density of For evaluating different methods of long term estrous mating and kidding and production of meat and milk synchronization followed by fixed time artificial during specific times of the year for strategic marketing insemination and to select the most efficient method, and other purposes (Baldassarre and Karatzas, 2004, during the breeding season 160 Persian downy does Zhao et al., 2010). In small ruminants, hormonal estrus were equally allocated to groups (n = 20/group). Estrus synchronization is achieved either by reducing the was synchronized using controlled internal drug release length of the luteal phase of the estrous cycle with devices alone (CIDR) or with equine chorionic prostaglandin F2α or by extending the cycle artificially gonadotropin (CIDR-eCG), intravaginal sponge with exogenous progesterone or more potent impregnated with 45 mg fluorgestone acetate alone progestagens (Hashemi et al., 2006, Abecia et al., (Sponge) or with eCG (Sponge-eCG), subcutaneous 2012). Progestogen administration is common and has auricular implant of 2 mg norgestomet alone (Implant) been used with or without accompanying treatments or with eCG (Implant-eCG) or two intramuscular such as gonadatropins or prostaglandin analogs.
    [Show full text]
  • Salivary 17 Α-Hydroxyprogesterone Enzyme Immunoassay Kit
    SALIVARY 17 α-HYDROXYPROGESTERONE ENZYME IMMUNOASSAY KIT For Research Use Only Not for use in Diagnostic Procedures Item No. 1-2602, (Single) 96-Well Kit; 1-2602-5, (5-Pack) 480 Wells Page | 1 TABLE OF CONTENTS Intended Use ................................................................................................. 3 Introduction ................................................................................................... 3 Test Principle ................................................................................................. 4 Safety Precautions ......................................................................................... 4 General Kit Use Advice .................................................................................... 5 Storage ......................................................................................................... 5 pH Indicator .................................................................................................. 5 Specimen Collection ....................................................................................... 6 Sample Handling and Preparation ................................................................... 6 Materials Supplied with Single Kit .................................................................... 7 Materials Needed But Not Supplied .................................................................. 8 Reagent Preparation ....................................................................................... 9 Procedure ...................................................................................................
    [Show full text]